ENDOMETRIAL RECEPTIVITY ANALYSIS (ERA) FOR PATIENTS WITH PGT-A NORMAL FROZEN EMBRYO TRANSFERS (FET): A RETROSPECTIVE ANALYSIS

Determine implantation rate (IR) and live birth rate (LBR) for patients undergoing a single PGT-A normal frozen embryo transfer according to standard progesterone timing versus ERA timed transfer. Retrospective cohort study at a large reproductive center from 2018 and 2019. Patients with or without a history of prior unsuccessful FET with PGT-A normal vitrified embryos completed ERA prior to analysis. The outcome of the first FET following ERA was assessed for all patients classified as receptive (FET according to standard protocol) and non-receptive (ERA adjusted FET). Outcomes were compared between PGT-A normal embryo transfer in patients with versus without ERA testing. Exclusion criteria were vaginal progesterone only, uterine factor and PGT-A untested embryos. Descriptive statistics were used to characterize outcomes. Chi square was used to compare dichotomous outcomes. The clinical outcomes of 307 ERA patients were compared to 1937 control FET cycles. For patients who underwent ERA testing, results were classified as receptive for 194 patients and non-receptive for 113 patients. A single PGT-A normal FET in the receptive group resulted in 67.5% and 43.2% IR and LBR, respectively. In comparison, the IR and LBR in the non-receptive and therefore ERA timed FET group were 74.3% and 46.9%, respectively. This difference was not statistically significant (p > 0.05). Patients without ERA testing had an IR and LBR of 62.2% and 50.2% for their last recorded transfer cycle. Compared to the ERA adjusted FET groups this was not statistically significantly different. There was no significant difference in IR or LBR for patients who did undergo ERA testing prior to PGT-A normal embryo FET compared to those whose endometrial receptivity status was unknown and therefore included both receptive and non-receptive patients. We recognize that a randomized controlled trial is needed to sufficiently assess the clinical utility of ERA testing.Tabled 1FrequencyPercentageERA Receptive – FET According To Standard ProtocolHCG +131/19467.50%HCG -63/19432.50%Live Birth84/19443.20%ERA Non-Receptive – ERA Adjusted FETHCG +84/11374.30%HCG -29/11325.70%Live Birth53/11346.90%FET For ERA Untested PatientsHCG +1205/193762.20%HCG -732/193737.80%Live Birth972/193750.20%*No comparisons between the 3 groups were statistically significant. Open table in a new tab